Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions.

"to calculate the principal component-based epigenetic clock for the horvath multi-tissue clock hannum clock dnamphenoage clock grimage clock and telomere length we used the custom r script available via github ( https://github com/morganlevinelab/pc-clocks ).; the pace of aging clock dunedinpace was calculated using the paceprojector function from the dunedinpace package available via github ( https://github com/danbelsky/dunedinpace )."

"CONFLICTS OF INTEREST: NC, VBD, RS, HW, AL, LT, and TLM are employees of TruDiagnostic."

"FUNDING: TruDiagnostic has provided funding for data analysis and IRB funding. The Institute for Hormonal Balance provided all other costs associated with testing and patient recruitment."

"For the evaluation of DQ treatment upon epigenetic age, 19 study participants were accrued from November 2020 to December 2020 at the Institute for Hormonal Balance, Orlando. The sample size was determined for the pilot study based on individuals who were willing to participate in the research. shows the demographic and clinical characteristics of these participants. Adults aged 40 and older able to comply with treatment plan and laboratory tests were included. Individuals with neoplastic cancer within 5 years prior to screening, immune disease, viral illness, cardiovascular or cerebrovascular disease, ischemic attack in the last 6 months, hepatitis or HIV, Body mass index higher than 40kg/m2, active infection, or previously used DQ were excluded. Informed consent was obtained from study participants. The FDA registered IRB (Institute for Regenerative and Cellular Medicine) approved this study, which is registered at ClinicalTrials.gov (NCT04946383) and which is an ongoing clinical trial to determine the effectiveness of Quercetin and Dasatinib supplements on the patient’s epigenetic aging rate. The treatment comprised 500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, and Wednesday (3 days in a row) per month for the duration of 6 months. Blood was collected at baseline, at the middle of the study (3 months), and at the end of the study (6 months). It is worth mentioning that three subjects stopped the treatment after 3 months due to nausea, prostate cancer diagnosis, and concern about the drug, respectively. Ethical Statement and Consent: The study involving human participants was reviewed and approved by the Institute for Regenerative and Cellular Medicine and registered at ClinicalTrials.gov (NCT04946383). The participants provided informed consent to participate in this study."